Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Kazia Therapeutics (KZIA) is an Australia-based clinical-stage company focused on developing drugs targeting oncology indications. Management also stated that the above results were consistent with the previously reported Kazia-sponsored mid-stage study, where paxalisib-treated patients achieved a median OS of 15.7 months compared with 12.7 months in patients receiving temozolomide chemotherapy. Based on the above analysis, Kazia is planning to request a meeting with the FDA to seek a potential pathway for ...